More early data revealed from landmark CRISPR gene editing human trial
Vertex and CRISPR Therapeutics presented new data from one of the first trials testing gene-editing therapy in human subjects. Fifteen months on from first patient treatment, the therapy is showing remarkable efficacy treating two rare blood diseases. Source of Article